CDC confirms at least 85 people experienced THC sickness from pizza place in Wisconsin
According to the report, at least 85 individuals, ranging from 1 to 91 years old, consumed food from the pizza shop in Stoughton, Wisconsin, between Oct. 22 and 24. The CDC said that the restaurant was in a building with a shared kitchen utilized by a state-licensed edible THC vendor.
Initial reports came as emergency medical services in the area reported to Public Health Madison and Dane County (PHMDC) that seven people had been taken to local hospitals for symptoms such as dizziness, sleepiness and anxiety. Each individual reported eating from the same local restaurant.
The seven individuals were treated at a Stoughton hospital with THC intoxication symptoms. One person who had eaten pizza from the same place reported that they had a positive THC test result without knowingly consuming any, prompting an outbreak investigation.
The restaurant closed immediately on Oct. 24, confirming to PHMDC about the THC vendor in the shared kitchen. According to the CDC report, the restaurant owner confirmed that they ran out of cooking oil on Oct. 22, using some from the shared kitchen to prepare dough.
Further investigation revealed that the oil used tested positive for THC, as the restaurant mistakenly used THC-infused oil from the cooperative kitchen to prepare dough. No criminal charges were filed as police deemed the contamination to be unintentional.
The restaurant reopened on Oct. 26 after deep cleaning and sanitation procedures approved by the Wisconsin Food Code.
The CDC report stated the following, '85 persons who responded to a health department questionnaire reported symptoms consistent with THC intoxication that occurred within 5 hours after eating food from a pizza restaurant.'
The restaurant apologized for the incident after initial reports from October 2024.
Click here to read the full report.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Solve the daily Crossword
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17 minutes ago
- Yahoo
What to know about chikungunya virus in China as US issues travel alert
The U.S. Centers for Disease Control and Prevention has issued a travel warning following an outbreak of a mosquito-borne illness called chikungunya in China. The CDC's warning centers on Guangdong Province, where the outbreak has exceeded 7,000 confirmed cases since June 2025, according to Chinese health officials. The outbreak in Guangdong Province has been linked to monsoon flooding, which created ideal breeding conditions for mosquitoes, which spread the virus that causes chikungunya. In the new travel warning, the CDC emphasized that vaccination is available and recommended for travelers. Dr. Todd Ellerin, chief of infectious disease at South Shore Health in Massachusetts, told ABC News that travelers to the region "should absolutely take precautions" against the illness. "Wear long sleeves and pants, use insect repellent with DEET, and use mosquito netting for babies too young for repellent," said Ellerin, who is not affiliated with the CDC. Here is what to know about the illness. How common is chikungunya? Chikungunya is not a new infection. It has been around since the 1950s, with outbreaks more commonly seen in tropical areas in recent decades. Globally, there have been about 240,000 infections since the start of 2025, according to the European Centre for Disease Prevention and Control. Chikungunya is not common in the United States. The CDC says there have not been any reported locally acquired cases since 2019. What are the symptoms of chikungunya? According to the CDC, common symptoms of the virus include sudden-onset high fever, severe joint pain (especially in the hands, wrists, ankles, and feet), muscle pain, headache, fatigue and skin rash. Georgia woman describes crippling pain of chikungunya virus Most people recover without medical intervention within seven to 10 days, but in some cases, symptoms can persist for weeks or months. What is the incubation period for chikungunya? Chikungunya typically has an incubation period of less than one week, according to Ellerin. "If it's been more than a week since you left a high-risk area, you're likely in the clear," he said. How is chikungunya treated? There is no specific antiviral treatment for chikungunya. Instead, care focuses on relieving symptoms while the body recovers. The CDC recommends rest, fluids, and medications like acetaminophen for pain and fever. NSAIDs may be used once dengue, another mosquito-borne disease, has been ruled out. Deaths from chikungunya are rare, according to the CDC. Is there a vaccine for chikungunya? There are two vaccines available in the U.S. that begin offering protection within about two weeks of a single dose. Cases of mosquito-borne viruses on the rise The CDC recommends vaccination for travelers visiting areas with active outbreaks, people spending extend time abroad -- typically six months or longer -- and laboratory workers who handle the virus. What contributes to the spread of chikungunya? Climate change is a major driver of chikungunya's global spread. "Warmer temperatures and increased rainfall are helping Aedes mosquitoes expand into new regions," Dr. Krutika Kuppalli of the division of infectious diseases at the University of Texas Southwestern Medical Center told ABC News. Veer Patel, M.D., is an emergency medicine doctor at Maimonides Medical Center and a member of the ABC News Medical Unit. Solve the daily Crossword
Yahoo
17 minutes ago
- Yahoo
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif., August 06, 2025--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. "Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx," said John Hanna, CEO of CareDx. "His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase." In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. "On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO," said John Hanna. "Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best." About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts CareDx Media Contacts Natasha Moshirian Wagnernwagner@ Investor RelationsCaroline Cornerinvestor@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 minutes ago
- Yahoo
FDA flags problems with two Boston Scientific heart devices tied to injuries and deaths
WASHINGTON (AP) — U.S. health regulators are warning doctors and patients about safety issues with two separate Boston Scientific heart devices recently linked to injuries and deaths. The Food and Drug Administration issued two alerts Wednesday about electrical problems tied to the company's heart-zapping defibrillator systems and a separate issue with a heart implant used to reduce stroke risk. The agency said the company's Endotak Reliance defibrillator wires can become calcified, leading to failures in delivering life-saving shocks to the heart, according to the FDA. Defibrillators are surgically placed in the upper chest, where they monitor irregular heartbeats and use electrical shocks to jolt the heart back to normal. As of July 24, Boston Scientific has reported 386 serious injuries and 16 deaths associated with this issue, the agency said. Ten of the deaths were judged to be due to the device failing to function properly, the company said in an email. Four were linked to attempts to surgically remove the devices from patients and two others were deemed unrelated to the implants. Boston Scientific's wires were distributed between 2002 and 2021 and are no longer available, the company noted in its letter to doctors. Some patients will need to have the devices replaced, though physicians should weigh the risks of the removal procedure. In a separate notice, the FDA said Boston Scientific recently updated instructions for implanting its Watchman device, which closes a portion of the heart's left atrium to reduce the risk of stroke. In a letter to physicians, the company noted that there is an increased risk of blockages in the bloodstream depending on the level of anesthesia for patients undergoing the initial implantation procedure. Watchman is an alternative to long-term treatment with blood thinners for patients at increased risk of stroke. As of July 30, the company has reported 120 serious injuries and 17 deaths related to the issue, the FDA said. A company investigation concluded that the safety issue 'is not associated with the design or manufacture of any component of the Watchman system. Heart devices, including defibrillators and other implants, are Boston Scientific's largest business, making up two-thirds of its $5 billion in revenue for the most recent quarter. Shares of Boston Scientific Corp. fell nearly 1.8 percent Wednesday to close at $102.95 in trading. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
